Targeting the RNA splicing machinery as a novel treatment strategy for pancreatic carcinoma

Gregory M. Hayes, Patricia E. Carrigan, Alison M. Beck, Laurence J Miller

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Aberrant patterns of pre-mRNA splicing have been established for many human malignancies, yet the mechanisms responsible for these tumor-specific changes remain undefined and represent a promising area for therapeutic intervention. Using immunohistochemistry, we have localized the expression of a central splicing regulator, serine-arginine protein kinase 1 (SRPK1), to the ductular epithelial cells within human pancreas and have further shown its increased expression in tumors of the pancreas, breast, and colon. Small interfering RNA-mediated down-regulation of SRPK1 in pancreatic tumor cell lines resulted in a dose-dependent decrease in proliferative capacity and increase in apoptotic potential. Coordinately, the disruption of SRPK1 expression resulted in enhanced sensitivity of tumor cells to killing by gemcitabine and/or cisplatin. A dose-dependent reduction in the phosphorylation status of specific SR proteins was detected following the downregulation of SRPK1 and is likely responsible for the observed alterations in expression of proteins associated with apoptosis and multidrug resistance. These data support SRPK1 as a new, potential target for the treatment of pancreatic ductular cancer that at present remains largely unresponsive to conventional therapies. Furthermore, these results support the development of innovative therapies that target not only specific splice variants arising during tumorigenesis but also the splice regulatory machinery that itself may be abnormal in malignant cells.

Original languageEnglish (US)
Pages (from-to)3819-3827
Number of pages9
JournalCancer Research
Volume66
Issue number7
DOIs
StatePublished - Apr 1 2006

Fingerprint

RNA Splicing
Arginine Kinase
Serine
Proteins
gemcitabine
Therapeutics
Pancreas
Down-Regulation
Neoplasms
Investigational Therapies
RNA Precursors
Multiple Drug Resistance
Pancreatic Carcinoma
Tumor Cell Line
Pancreatic Neoplasms
Small Interfering RNA
Cisplatin
Colon
Carcinogenesis
Epithelial Cells

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Targeting the RNA splicing machinery as a novel treatment strategy for pancreatic carcinoma. / Hayes, Gregory M.; Carrigan, Patricia E.; Beck, Alison M.; Miller, Laurence J.

In: Cancer Research, Vol. 66, No. 7, 01.04.2006, p. 3819-3827.

Research output: Contribution to journalArticle

Hayes, Gregory M. ; Carrigan, Patricia E. ; Beck, Alison M. ; Miller, Laurence J. / Targeting the RNA splicing machinery as a novel treatment strategy for pancreatic carcinoma. In: Cancer Research. 2006 ; Vol. 66, No. 7. pp. 3819-3827.
@article{64a47b4566a14fd396869d676cb0308b,
title = "Targeting the RNA splicing machinery as a novel treatment strategy for pancreatic carcinoma",
abstract = "Aberrant patterns of pre-mRNA splicing have been established for many human malignancies, yet the mechanisms responsible for these tumor-specific changes remain undefined and represent a promising area for therapeutic intervention. Using immunohistochemistry, we have localized the expression of a central splicing regulator, serine-arginine protein kinase 1 (SRPK1), to the ductular epithelial cells within human pancreas and have further shown its increased expression in tumors of the pancreas, breast, and colon. Small interfering RNA-mediated down-regulation of SRPK1 in pancreatic tumor cell lines resulted in a dose-dependent decrease in proliferative capacity and increase in apoptotic potential. Coordinately, the disruption of SRPK1 expression resulted in enhanced sensitivity of tumor cells to killing by gemcitabine and/or cisplatin. A dose-dependent reduction in the phosphorylation status of specific SR proteins was detected following the downregulation of SRPK1 and is likely responsible for the observed alterations in expression of proteins associated with apoptosis and multidrug resistance. These data support SRPK1 as a new, potential target for the treatment of pancreatic ductular cancer that at present remains largely unresponsive to conventional therapies. Furthermore, these results support the development of innovative therapies that target not only specific splice variants arising during tumorigenesis but also the splice regulatory machinery that itself may be abnormal in malignant cells.",
author = "Hayes, {Gregory M.} and Carrigan, {Patricia E.} and Beck, {Alison M.} and Miller, {Laurence J}",
year = "2006",
month = "4",
day = "1",
doi = "10.1158/0008-5472.CAN-05-4065",
language = "English (US)",
volume = "66",
pages = "3819--3827",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Targeting the RNA splicing machinery as a novel treatment strategy for pancreatic carcinoma

AU - Hayes, Gregory M.

AU - Carrigan, Patricia E.

AU - Beck, Alison M.

AU - Miller, Laurence J

PY - 2006/4/1

Y1 - 2006/4/1

N2 - Aberrant patterns of pre-mRNA splicing have been established for many human malignancies, yet the mechanisms responsible for these tumor-specific changes remain undefined and represent a promising area for therapeutic intervention. Using immunohistochemistry, we have localized the expression of a central splicing regulator, serine-arginine protein kinase 1 (SRPK1), to the ductular epithelial cells within human pancreas and have further shown its increased expression in tumors of the pancreas, breast, and colon. Small interfering RNA-mediated down-regulation of SRPK1 in pancreatic tumor cell lines resulted in a dose-dependent decrease in proliferative capacity and increase in apoptotic potential. Coordinately, the disruption of SRPK1 expression resulted in enhanced sensitivity of tumor cells to killing by gemcitabine and/or cisplatin. A dose-dependent reduction in the phosphorylation status of specific SR proteins was detected following the downregulation of SRPK1 and is likely responsible for the observed alterations in expression of proteins associated with apoptosis and multidrug resistance. These data support SRPK1 as a new, potential target for the treatment of pancreatic ductular cancer that at present remains largely unresponsive to conventional therapies. Furthermore, these results support the development of innovative therapies that target not only specific splice variants arising during tumorigenesis but also the splice regulatory machinery that itself may be abnormal in malignant cells.

AB - Aberrant patterns of pre-mRNA splicing have been established for many human malignancies, yet the mechanisms responsible for these tumor-specific changes remain undefined and represent a promising area for therapeutic intervention. Using immunohistochemistry, we have localized the expression of a central splicing regulator, serine-arginine protein kinase 1 (SRPK1), to the ductular epithelial cells within human pancreas and have further shown its increased expression in tumors of the pancreas, breast, and colon. Small interfering RNA-mediated down-regulation of SRPK1 in pancreatic tumor cell lines resulted in a dose-dependent decrease in proliferative capacity and increase in apoptotic potential. Coordinately, the disruption of SRPK1 expression resulted in enhanced sensitivity of tumor cells to killing by gemcitabine and/or cisplatin. A dose-dependent reduction in the phosphorylation status of specific SR proteins was detected following the downregulation of SRPK1 and is likely responsible for the observed alterations in expression of proteins associated with apoptosis and multidrug resistance. These data support SRPK1 as a new, potential target for the treatment of pancreatic ductular cancer that at present remains largely unresponsive to conventional therapies. Furthermore, these results support the development of innovative therapies that target not only specific splice variants arising during tumorigenesis but also the splice regulatory machinery that itself may be abnormal in malignant cells.

UR - http://www.scopus.com/inward/record.url?scp=33645746620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645746620&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-05-4065

DO - 10.1158/0008-5472.CAN-05-4065

M3 - Article

C2 - 16585209

AN - SCOPUS:33645746620

VL - 66

SP - 3819

EP - 3827

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 7

ER -